Project Grant HT94252310451

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $1,499,886.00 to Astrocyte Pharmaceuticals Inc. to advance the development of an oral tablet formulation of the compound AST-004 for the treatment of moderate traumatic brain injury (TBI). The key objectives of this award are to (1) verify the efficacy of the oral AST-004...

The National Institute of Neurological Disorders and Stroke (NINDS), through the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), awarded Versapeutics Inc. a $2,380,552 federal project grant on September 18, 2023 to conduct toxicology and efficacy studies of their novel antibody therapeutic Versamab-101 for treating spinal cord injury. Versapeutics, a for-profit biotechnology company, will utilize the funding to evaluate the safety profile and determine...

The National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), has awarded a $23,579,701 Cooperative Agreement to Ensysce Biosciences, Inc. to support the clinical development of PF614-MPAR, an opioid product with oral overdose protection. The key objectives of this project are to continue the clinical development of PF614-MPAR, a combination product of a trypsin-activated abuse protection (TAAP) oxycodone prodrug and a trypsin inhibitor...

The Defense Health Agency awarded a $1,973,398 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Azevan Pharmaceuticals Inc. in Bethlehem, PA. The grant supports the development of a new drug to prevent the effects of mild traumatic brain injury (TBI) or concussion. The research project will be conducted over a 2-year period from June 2024 to June 2026. The goal is to advance the development of an innovative medical solution to address this critical...

This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...

This SBIR Phase II award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $2,776,138 to Neurocarrus Inc. to develop a novel biologic drug called N-001 for the management of acute nociceptive pain. The funding will be used to optimize the production and formulation of N-001, establish manufacturing standards and controls, and conduct pivotal preclinical studies to demonstrate the safety and...

This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $3,138,031.00 to Sparian Biosciences Inc. (doing business as Palion Therapeutics) to conduct clinical development of SBS-147, a first-in-class non-opioid oral arylepoxamide agonist for the treatment of acute and chronic pain. The award will fund a Phase 1 SAD/MAD clinical trial to characterize the safety, tolerability, and...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $944,676 to Haima Therapeutics LLC, a woman-owned small business, to develop a novel platelet-inspired nanotechnology to restore hemostasis in patients on antiplatelet agents. The goal is to create a synthetic, donor-independent therapeutic that can effectively restore hemostatic function in traumatic brain injury (TBI) patients taking P2Y12 inhibitors, which...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is focused on elucidating the role of metabolic regulation and AMPK activation in modulating neutrophil extracellular traps (NETs) formation and inflammation following traumatic brain injury (TBI). The $453,860 award, with a period of performance from June 1, 2025 to April 30, 2030, will...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award provides $274,855 to Mito-Biotherapeutics, Inc. to develop a novel fusion protein construct (NFP) that can cross the blood-brain barrier and deliver a therapeutic payload to repair mitochondrial DNA damage in neurons following traumatic brain injury (TBI). The project aims to attenuate neurological damage and prevent the progression of TBI to neurodegenerative diseases like...